{"schema_version":"secwatch.filing_event.v1","accession":"0000879407-25-000007","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.552520+00:00","generated_at":"2026-05-17T06:56:38.203735+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arrowhead files declaratory judgment suit against Ionis over '333 patent for plozasiran","bullets":["Arrowhead filed a declaratory judgment action in Delaware against Ionis claiming the '333 patent is invalid and not infringed by plozasiran.","Plozasiran is Arrowhead's RNAi therapy for familial chylomicronemia syndrome (FCS); Phase 3 PALISADE study showed up to 80% triglyceride reduction.","FDA PDUFA action date for plozasiran is November 18, 2025.","Ionis sent a September 3, 2025 letter alleging patent infringement and threatening suit; Arrowhead acted preemptively.","Arrowhead's complaint alleges the '333 patent claims are invalid for anticipation and lack of written description/enablement."],"urls":{"canonical":"https://secwatch.observer/filing/0000879407-25-000007","json":"https://secwatch.observer/filing/0000879407-25-000007.json","markdown":"https://secwatch.observer/filing/0000879407-25-000007.md","text":"https://secwatch.observer/filing/0000879407-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000087940725000007/0000879407-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000087940725000007/arwr-20250910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:56:38.203735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}